Project Details
Description
Translation of a novel combination therapy approach for non-Hodgkin lymphoma .
Diffuse large B-cell lymphoma is the most common type of Non-hodgkin’s lymphoma (NHL) with limited treatment
options in the relapsed or refractory (r/r) setting. This is true in humans and dogs. Immunotherapy with
checkpoint inhibitors (CPIs) have demonstrated durable efficacy for Hodgkin’s lymphoma, but poor efficacy for
NHL. There is an unmet clinical understand mechanisms of immunotherapy resistance and develop therapeutic
approaches to improve clinical response for patients with advanced NHL and other cancers. DLBCL in
companion dogs (cDLBCL) is treated with similar chemotherapy protocols and has a similarly poor prognosis in
the r/r setting as human DLBCL. While genomic comparison shows limited overlap of the mutational landscape
in canine and human DLBCLs, preliminary comparison of the tumor microenvironment (TME) shows
conservation of stromal and immune compartments between the two species. Thus, cDLBLCL provide
opportunities to prospectively investigate clinical toxicities and mechanisms of clinical response in a clinically
realistic setting that recapitulates the pathology, heterogeneity, and TME of human cancers.
Vesicular stomatitis virus (VSV) is a rapidly replicating, robustly immunogenic oncolytic virus (OV) platform that
has been engineered for safe systemic therapy of disseminated cancer. Intravenous (IV) VSV therapy was
shown preclinically in murine tumor models to rapidly infect, spread within, and kill tumor cells, and induce robust
intratumoral immune infiltration, sensitizing tumors to checkpoint blockade. ONIx (oncoimmunology accelerator)
is a novel, dual targeted CPI that targets both innate and adaptive mechanisms of tumor immune suppression
to enhance antitumor immune responses mediated by macrophages and T-cells. We hypothesize that
oncolytic VSV and ONIx will have complementary mechanisms of action (MOA), working in concert to kill
tumor cells by direct viral lysis as well as phagocytosis, increase availability of tumor associated antigens (TAAs),
promote antigen presentation and activate anti-tumor T-cell responses, to enhance immune mediated tumor
killing and improve clinical responses in r/r DLBCL. Our proposal merges the expertise and resources of
leading institutions in OV development (Mayo Clinic), comparative oncology (University of Minnesota), and
lymphoma immunotherapy (Mayo Lymphoma SPORE) to perform a veterinary trial and correlative studies to
evaluate the safety and preliminary efficacy of this novel combination therapy in r/r cDLBCL. The proposed
studies will yield valuable insights into how an IV administered OV can infect heterogeneous DLBCL tumors and
agitate the TME; if this disruption enhances the ability of CPIs (and potentially other immunotherapies) to activate
immune mediated tumor killing; and how the tumor architecture differs in the context of clinical response versus
non-response. The heterogeneity inherent in naturally occurring cDLBCL will inform the clinical utility of this
combination therapy, define MOA, and identify biomarkers that can be explored clinically in human DLBCL.
Status | Active |
---|---|
Effective start/end date | 9/1/22 → 8/31/24 |
Funding
- National Cancer Institute: $584,891.00
- National Cancer Institute: $625,851.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.